Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products

April 20, 2026 at 09:58 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

2149611199 1 1 Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products

The Company’s Health Canada-licensed GMP psychedelic manufacturing platform ready to serve emerging demand for ibogaine, a naturally occurring alkaloid under investigation for opioid use disorder, PTSD, and traumatic brain injury Vancouver, British Columbia–(April 20, 2026) – Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FSE: 8BN) (the “Company” or “Optimi“), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug … Continue reading

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol	Price	Change (%)
AMZN	276.54	+2.99 (1.09%)
AAPL	287.44	+3.26 (1.15%)
AMD	418.50	+63.24 (17.80%)
BAC	53.70	+0.58 (1.08%)
GOOG	393.38	+9.11 (2.37%)
META	612.46	+7.50 (1.24%)
MSFT	412.78	+1.40 (0.34%)
NVDA	207.25	+10.75 (5.47%)
ORCL	192.73	+7.38 (3.98%)
TSLA	398.96	+9.59 (2.46%)

Symbol

Price

Change (%)

AMZN

276.54

+2.99 (1.09%)

AAPL

287.44

+3.26 (1.15%)

AMD

418.50

+63.24 (17.80%)

BAC

53.70

+0.58 (1.08%)

GOOG

393.38

+9.11 (2.37%)

Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products

More News

Recent Quotes

Sections

Services

Follow Us